| abstract |
[PROBLEMS] To provide a smooth muscle contraction inhibitor that can be stably supplied, inhibiting the smooth muscle contraction not dependent upon calcium ion without influencing the normal smooth muscle contraction dependent upon calcium ion, and further provide a therapeutic agent and preventive agent for circulatory system diseases and an Fyn/Rho kinase signaling cascade inhibitor. [MEANS FOR SOLVING PROBLEMS] There are provided a smooth muscle contraction inhibitor, therapeutic agent and preventive agent for circulatory system diseases and Fyn/Rho kinase signaling cascade inhibitor that are characterized by containing at least one member selected from the group consisting of octadecapentaenoic acid, octadecatetraenoic acid, and salts and esters thereof. Further, there are provided a smooth muscle contraction inhibitor, therapeutic agent and preventive agent for circulatory system diseases and Fyn/Rho kinase signaling cascade inhibitor that are characterized by being based on a smooth muscle contraction inhibitor containing a lipid whose at least one acyl chain is at least one member selected from the group consisting of octadecapentaenoic acid, octadecatetraenoic acid and eicosapentaenoic acid. |